Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15371185 | 0.78 | CA2 (0.40) | PRMT6CA2 | |
| SCHEMBL23299149 | 0.78 | CA2 (0.46) | PRMT6TP53THRBALDH1A1LMNA | |
| SCHEMBL21311972 | 0.74 | — | — | |
| SCHEMBL2719762 | 0.72 | PRMT6 (0.63) | PRMT6TP53THRBALDH1A1NPC1 | |
| SCHEMBL15371157 | 0.72 | PLAU (0.53) | PRMT6TP53ALDH1A1NPC1RAB9A | |
| SCHEMBL9917335 | 0.71 | PRMT6 (0.50) | PRMT6TP53THRBALDH1A1NPC1 | |
| SCHEMBL23432958 | 0.71 | PRMT6 (0.61) | PRMT6TP53THRBALDH1A1NPC1 | |
| SCHEMBL3801388 | 0.70 | PRMT6 (0.48) | PRMT6TP53THRBALDH1A1NPC1 | |
| SCHEMBL18355168 | 0.69 | PRMT6 (0.59) | PRMT6TP53THRBALDH1A1NPC1 | |
| SCHEMBL8501787 | 0.69 | PRMT6 (0.59) | PRMT6TP53THRBALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119386-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-11136320-B2 | Fused ring derivative used as FGFR4 inhibitor | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136320-B2 | Fused ring derivative used as FGFR4 inhibitor | FGFR4, FGFR1, FGFR3 | PRMT6 1972/4885TP53 1083/4885THRB 1616/4885 |
| US-20220119386-A1 | FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR | FGFR4, FGFR1, FGFR3 | PRMT6 1972/4885TP53 1083/4885THRB 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.